Plasma Platelet-activating Factor (PAF) Levels and Desmopressin Response in Children with Hemophilia A and von Willebrand's Disease

• References

• 1 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21.
• 2 Lusher JM. Response to 1-Deamino-8-D-Arginin Vazopressin in von Willebrand’s disease. Haemostasis 1994; 24: 276-84.
• 3 Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993; 154: 496-505.
• 4 Imaizumi T, Stafforini DM, Yamada Y, McInytre T, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Int Med 1995; 238: 5-20.
• 5 Denizot Y, Rougier F, Dupuis F, Verger C. PAF and hematopoiesis. VIII. Biosynthesis and metabolism of PAF by human bone marrow stromal cells. Exp Haematol 1996; 24: 1327-32.
• 6 Salari H. Solid phase extraction and reversed-phase high performance liquid chromatographic technique for isolation and estimation of platelet-activating factor in plasma. J Chromatogr 1986; 382: 89-98.
• 7 Stafforini DM, Prescott SM, Zimmerman GA, McInytre TM. Platelet-activating factor acetylhydrolase activity in human tissues and blood cells. Lipids 1991; 26: 979-85.